Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

A Genome-wide Study of Co… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor

Artikel i vetenskaplig tidskrift
Författare Tara M Stanne
Maja Olsson
Erik Lorentzen
Annie Pedersen
Anders Gummesson
A. Gils
Katarina Jood
G. Engstrom
O. Melander
P. J. Declerck
Christina Jern
Publicerad i Thrombosis and Haemostasis
Volym 118
Nummer/häfte 2
Sidor 298-308
ISSN 0340-6245
Publiceringsår 2018
Publicerad vid Institutionen för biomedicin, avdelningen för patologi
Core Facilities, Bioinformatics
Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap
Sidor 298-308
Språk en
Länkar doi.org/10.1160/TH17-04-0249
Ämnesord thrombin-activatable fibrinolysis inhibitor, fibrinolysis inhibitors, plasma levels, genome-wide, plasma procarboxypeptidase b, coronary-artery-disease, tafi antigen, levels, ischemic-stroke, mediated activation, risk, identification, polymorphisms, genotype, expression, Hematology, Cardiovascular System & Cardiology
Ämneskategorier Kardiologi, Kardiovaskulär medicin, Hematologi

Sammanfattning

Thrombin-activatable fibrinolysis inhibitor (TAFI) plays a central role in haemostasis, and plasma TAFI concentrations are heritable. Candidate gene studies have identified several variants within the gene encoding TAFI, CPB2, that explain part of the estimated heritability. Here, we describe an exploratory genome-wide association study to identify novel variants within and outside of the CPB2 locus that influence plasma concentrations of intact TAFI and/or the extent of TAFI activation (measured by released TAFI activation peptide, TAFI-AP) amongst 3,260 subjects from Southern Sweden. We also explored the role of rare variants on the HumanExome BeadChip. We confirmed the association with previously reported common variants in CPB2 for both intact TAFI and TAFI-AP, and discovered novel associations with variants in putative CPB2 enhancers. We identified a gene-based association with intact TAFI at CPB2 (PSKAT-O = 2.8 x 10(-8)), driven by two novel rare nonsynonymous single nucleotide polymorphisms (SNPs; I420N and D177G). Carriers of the rare variant of D177G (rs140446990; MAF 0.2%) had lower intact TAFI and TAFI-AP concentrations compared with non-carriers (intact TAFI, geometricmean 53 vs. 78%, PT-test < 5 x 10(-7); TAFI-AP 63 vs. 99%, P(T-tes)t = 7.2 x 10(-4)). For TAFI-AP, we identified a genome-wide significant association at an intergenic region of chromosome 3p14.1 and five gene-based associations (all PSKAT-O = 5 x 10(-6)). Using well-characterized assays together with a genome-wide association study and a rare-variant approach, we verified CPB2 to be the primary determinant of TAFI concentrations and identified putative secondary loci (candidate variants and genes) associated with intact TAFI and TAFI-AP that require independent validation.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?